Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Healius Limited ( (AU:HLS) ).
Healius Limited has disclosed a change in director Katherine Ostin’s interests in the company’s securities, following an on‑market purchase of additional fully paid ordinary shares. Ostin’s indirect holding, through Nitso Pty Limited as trustee for The Ostin‑Shortus Family Trust, increased by 8,547 shares at a price of $0.585 per share, lifting her indirect stake while her direct shareholding and existing share rights remained unchanged.
The transaction, which did not involve any related contracts or trading during a closed period, modestly expands Ostin’s overall exposure to Healius equity. This incremental increase in director share ownership may be viewed positively by investors as a signal of confidence in the company’s prospects, although it does not in itself indicate any broader strategic shift at the healthcare services group.
The most recent analyst rating on (AU:HLS) stock is a Sell with a A$0.65 price target. To see the full list of analyst forecasts on Healius Limited stock, see the AU:HLS Stock Forecast page.
More about Healius Limited
Healius Limited is an Australian healthcare company operating pathology laboratories, diagnostic imaging centres and day hospitals across the country. The company provides essential medical testing and diagnostic services to patients, doctors and healthcare providers, positioning it as a key participant in Australia’s clinical and diagnostic services market.
Average Trading Volume: 2,788,552
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$446.6M
See more data about HLS stock on TipRanks’ Stock Analysis page.